Notably, the MC4R agonist setmelanotide (IMCIVREE) was recently approved by the US FDA to manage BBS-associated weight gain and is under evaluation for additional therapeutic effects in BBS patients (45, 46). This evidence concerns the gene MC4R and Bardet-Biedl syndrome.